Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel

Nicola F Smith1, Milin R Acharya, Neil Desai

  • 1Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

Cancer Biology & Therapy
|October 8, 2005
PubMed

Insights

Organic anion transporting polypeptide 1B3 (OATP1B3) significantly increases uptake of paclitaxel and docetaxel in liver cells. This transporter may explain patient variability in taxane drug response and toxicity.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Hepatology

Background:

  • Interindividual variability in paclitaxel and docetaxel pharmacokinetics, toxicity, and response is significant and largely unexplained.
  • This variability may stem from differences in drug uptake and transport, influencing elimination pathways.

Purpose of the Study:

  • To investigate the role of liver-specific organic anion transporting polypeptide (OATP) family members, specifically OATP1B1 and OATP1B3, in the uptake of taxanes (paclitaxel and docetaxel).

Main Methods:

  • Accumulation of [3H]docetaxel and [3H]paclitaxel was studied in Xenopus laevis oocytes expressing OATP1B1 or OATP1B3.
  • Transport kinetics, inhibition by various compounds, and effects of the formulation excipient Cremophor were assessed.

Main Results:

  • Oocytes expressing OATP1B3 showed significantly higher uptake of both docetaxel (2.2-fold) and paclitaxel (3.3-fold) compared to controls.
  • OATP1B3-mediated paclitaxel transport was saturable and inhibited by Cremophor, cyclosporin A, glycyrrhizic acid, and hyperforin.
  • Cremophor significantly affected hepatic uptake of paclitaxel in mice.

Conclusions:

  • OATP1B3 is identified as a key regulator of hepatic uptake for paclitaxel and docetaxel.
  • OATP1B3 likely plays a crucial role in the observed interindividual variability in patient response to taxane chemotherapy.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...